| Literature DB >> 30646234 |
James W T Toh1,2,3, Kevin Phan1, Kerry Hitos1,2,3, Nimalan Pathma-Nathan1,3, Toufic El-Khoury1,3,4, Arthur J Richardson1,3, Gary Morgan1,3, Alexander Engel1,5, Grahame Ctercteko1,3.
Abstract
Importance: There has been a resurgence of interest in the use of mechanical bowel preparation (MBP) and oral antibiotics (OAB) before elective colorectal surgery. Until now, clinical trials and meta-analyses have not compared all 4 approaches (MBP with OAB, OAB only, MBP only, or no preparation) simultaneously. Objective: To perform a network meta-analysis to clarify which approach in colorectal surgery is associated with the lowest rate of surgical site infection (SSI). Data Sources: Five electronic databases were searched, including PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, ACP Journal Club. and Database of Abstracts of Review of Effectiveness from database inception to November 27, 2017. Study Selection: Only data from randomized clinical trials were included. Inclusion criteria were RCTs that reported on SSI rates or other complications based on MBP or OAB status. Quality of studies was appraised by the Cochrane Collaboration risk of bias tool. Data Extraction and Synthesis: The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Main Outcomes and Measures: Total, incisional, and organ/space SSI rates. Secondary outcomes included rates of anastomotic leak, mortality, readmissions/reoperations, urinary tract infection, and pulmonary complications.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30646234 PMCID: PMC6324461 DOI: 10.1001/jamanetworkopen.2018.3226
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Characteristics of Included Studies and Randomized Patients
| Source | Study Period | Male, No.:Female, No. | Treatment 1, Patients, No. | Treatment 2, Patients, No. | Oral Solution | Left, Right, or Mixed Location | Laparoscopic, Open, or Mixed Approach | Intravenous Antibiotic Type | Oral Antibiotic Type |
|---|---|---|---|---|---|---|---|---|---|
| Ali,[ | NA | NA | 109 | 101 | PEG | Mixed | Open | Ceftriaxone 2 g, metronidazole 1 g | NA |
| Bertani et al,[ | 2007-2010 | 65:49 | 114 | 115 | PEG | Mixed | Mixed | Cefoxitin 2 g and then 1 g administered at 4, 12, and 24 h | NA |
| Bhat and Chakraborty,[ | 2012-2014 | 56:42 | 98 | 104 | PEG | Mixed | Open | Ceftriaxone 1 g, metronidazole 500 mg, continued for 48 h | NA |
| Bhattacharjee et al,[ | 2010-2013 | 21:17 | 38 | 33 | PEG | Mixed | Open | Cefuroxime 1.5 g, metronidazole 500 mg, 1 h before surgery | NA |
| Bretagnol et al,[ | 2007-2009 | 56:33 | 89 | 89 | Senna, povidone-iodine enema | Left | Mixed | Ceftriaxone1 g, metronidazole 500 mg, continued every 2 h during the surgical procedure | NA |
| Bucher et al,[ | 2001-2003 | 47:31 | 78 | 75 | PEG | Left | Open | Ceftriaxone 1 g, metronidazole 500 mg, continued for at least 24 h | NA |
| Burke et al,[ | 1988-1992 | 52:30 | 82 | 87 | Sodium picosulfate | Left | Open | Ceftriaxone 1 g, metronidazole 500 mg, then metronidazole 500 mg administered at 8 h and 16 h | NA |
| Contant et al,[ | 1998-2004 | 337:333 | 670 | 684 | PEG, bisacodyl | Mixed | Open | As per institution guidelines | NA |
| Fa-Si-Oen et al,[ | 1998-2002 | 58:67 | 125 | 125 | PEG | Mixed | Open | Cephazolin 2 g, metronidazole 1.5 g | NA |
| Khan et al,[ | NA | NA | 51 | 51 | PEG | Mixed | Open | Ceftriaxone 2 g, metronidazole 1 g | NA |
| Miettinen et al,[ | 1994-1996 | 68:70 | 138 | 129 | PEG | Mixed | Open | Ceftriaxone 2 g, metronidazole 1 g | NA |
| Pena-Soria et al,[ | 2001-2007 | 35:29 | 65 | 64 | PEG | Mixed | Open | Gentamicin 80 mg, metronidazole 500 mg, repeat dose at 8, 16, and 24 h | NA |
| Platell et al,[ | 2000-2005 | NA | 147 | 147 | PEG | Mixed | Open | Ticarcillin-clavulanate 3.1 g | NA |
| Ram et al,[ | 1999-2002 | 99:65 | 164 | 165 | Sodium phosphate | Mixed | Open | Ceftriaxone 1 g, metronidazole 500 mg, continued for 48 h | NA |
| Saha et al,[ | 2008-2010 | NA | 32 | 31 | PEG | Left | Open | Ceftriaxone 1 g, metronidazole 500 mg, continued for 36 h | NA |
| Santos et al,[ | 1991-1992 | NA | 72 | 77 | Laxative, mannitol | Mixed | Open | Cephalothin 1 g, metronidazole 500 mg, then cephalothin 1 g given at 6 h and 12 h and metronidazole 500 mg at 8 h and 16 h | NA |
| Sasaki et al,[ | 2009 | 17:21 | 38 | 41 | PEG | Mixed | Mixed (laparoscopic data given) | Flomoxef 1 g, continued every 3 h during surgery | NA |
| Reddy et al,[ | NA | 22:20 | 42 | 22 | Sodium picosulfate, magnesium citrate | Mixed | Open | NA | Neomycin 1 g, 3 doses 1 d before surgery, with or without synbiotic |
| Zmora et al,[ | 1997-2000 | 103:84 | 187 | 193 | PEG | Mixed | Open | Intravenous antibiotics, type not specified, at induction of anesthesia and continued at least 24 h | Neomycin, erythromycin, 3 doses before surgery |
| Zmora et al,[ | 1997-2001 | 67:53 | 120 | 129 | PEG | Left | Open | Metronidazole 500 mg, gentamicin 240 mg, ampicillin 1 g | Neomycin 1 g, erythromycin 1 g, 3 doses 1 d before surgery |
| Beggs et al,[ | NA | 25:21 | 46 | 51 | As per surgeon | Mixed | Open | Metronidazole 500 mg, then continued every 8 h for a further 5 doses | Metronidazole 200 mg for 4 d before surgery (all patients received neomycin 1 g orally 4 times daily for 5 d before surgery) |
| Dion et al,[ | NA | NA | 39 | 39 | Magnesium citrate | Mixed | Open | Metronidazole 1 g, then 500 mg at 8 h and 16 h | Metronidazole 750 mg 3 times daily for 2 d before surgery (all patients received 1 g of neomycin 3 times daily 1 d before surgery) |
| Espin-Basany et al,[ | NA | 130:70 | 200 | 100 | Sodium phosphate | Mixed | Open | Cefoxitin 1 g, then continued 1 g at 8 h and 16 h | Neomycin 1 g, metronidazole 1 g, either 3 doses or 1 dose 1 d before surgery |
| Hata et al,[ | 2007-2012 | 153:136 | 289 | 290 | Picosulfate, magnesium citrate | Mixed | Laparoscopic | Metronidazole 750 mg, cefmetazole 1 g, then every 3 h during surgery | Kanamycin 1 g, metronidazole 750 mg, 2 doses 1 d before surgery |
| Ikeda et al,[ | 2013-2014 | 142:113 | 255 | 256 | Picosulfate, magnesium citrate | Mixed | Laparoscopic | Cefmetazole 1 g, then every 3 h during surgery, continued for 24 h | Kanamycin 1 g, metronidazole 750 mg, 2 doses 1 d before surgery |
| Ishida et al,[ | 1998-2000 | 47:25 | 72 | 71 | PEG | Mixed | Open | Cefotiam 1 g, then 1 g at completion of surgery, then 1 g twice daily for 2 d (6 doses in total) | Kanamycin 2 g/d, erythromycin 1.6 g/d, 4 doses for 2 d before surgery |
| Kling and Dahlgren,[ | 1985-1986 | 14:13 | 27 | 27 | Bisacodyl, magnesium sulfate | Mixed | Open | Metronidazole 1.5 g, ceftriaxone 2 g | Neomycin 1 g, erythromycin 1 g, 3 doses 1 d before surgery |
| Kobayashi et al,[ | 2001-2004 | 154:88 | 242 | 242 | PEG | Mixed | Open | Cefmetazole 1 g, then every 3 h during surgery, continued daily for 72 h | Kanamycin 1 g, erythromycin 400 mg, 3 doses 1 d before surgery |
| Lau et al,[ | 1981-1987 | 1.3:1 | 65 | 67 | Bisacodyl, magnesium sulfate | Mixed | Open | Metronidazole 500 mg, gentamicin 2 mg/kg, then repeated at 8 h and 16 h | Neomycin 1 g, erythromycin 1 g, 3 doses 1 d before surgery |
| Lazorthes et al,[ | 1979-1980 | 20:10 | 30 | 30 | Magnesium sulfate | Mixed | Open | Cephradine 2 g, metronidazole 500 mg, with or without gentamicin 2 mg/kg | Kanamycin 1 g, metronidazole 250 mg, 4 doses daily for 3 d before surgery |
| Lewis,[ | 1992-1995 | NA | 109 | 106 | Sodium phosphate | Mixed | Open | Amikacin 1 g, metronidazole 1 g | Neomycin 2 g, metronidazole 2 g, 2 doses 1 d before surgery |
| Oshima et al,[ | 2006-2009 | 55:42 | 97 | 98 | Magnesium citrate | Mixed | Open | Flomoxef, then every 3 h during surgery | Kanamycin 500 mg, metronidazole 500 mg, 3 doses 1 d before surgery |
| Playforth et al,[ | NA | 31:30 | 61 | 58 | Mannitol | Mixed | Open | Metronidazole 500 mg | Neomycin 1 g every 6 h, metronidazole 200 mg every 8 h, 1 d before surgery |
| Raahave et al,[ | NA | 21:29 | 50 | 50 | Bisacodyl, magnesium sulfate | Mixed | Open | Cefotaxime 2 g, then 2 g at 6 h and 12 h | Neomycin 1 g, erythromycin 1 g, 3 doses 1 d before surgery (ampicillin 2 g powdered in wound at closure) |
| Reddy et al,[ | NA | 22:20 | 42 | 24 | Picosulfate, magnesium citrate | Mixed | Open | NA | Neomycin 1 g, 3 doses 1 d before surgery, with or without synbiotic |
| Sadahiro et al,[ | 2008-2011 | 49:51 | 100 | 95 | Picosulfate, PEG | Mixed | Mixed | Flomoxef 1 g | Kanamycin 500 mg, metronidazole 500 mg, 3 doses 1 d before surgery |
| Stellato et al,[ | 1987 | NA | 38 | 45 | Picosulfate, PEG | Mixed | Open | Cefoxitin | Neomycin, erythromycin |
| Weaver et al,[ | NA | NA | 29 | 31 | As per surgeon | Mixed | Open | Ceftriaxone 2 g, metronidazole 1.5 g | Neomycin 1 g, erythromycin 1 g, 3 doses 1 d before surgery |
| Yabata et al,[ | NA | 23:17 | 40 | 51 | PEG | Mixed | Open | Cefmetazole 1 g, then every 3 h during surgery | Tobramycin 30 mg, metronidazole 250 mg, 3 doses daily for 3 d before surgery (tobramycin 30 mg with saline instilled into lumen during surgery) |
| Reddy et al,[ | NA | 11:13 | 24 | 22 | Picosulfate, magnesium citrate | Mixed | Open | NA | Neomycin 1 g, 3 doses 1 d before surgery, with or without synbiotic |
Abbreviations: MBP, mechanical bowel preparation; NA, not applicable; OAB, oral antibiotics; PEG, polyethylene glycol.
The study by Reddy et al[34] reports on MBP with OAB, MBP only, and OAB only.
Sex breakdown for the fourth and fifth columns.
Figure 1. Network Plots of the 8 Outcomes Showing Direct Comparisons and Indirect Comparisons Between Treatment Groups Based on Mechanical Bowel Preparation (MBP) and Oral Antibiotic (OAB) Status
Comparison networks were explored by representing each of the 4 bowel preparation approaches as a node, with lines between nodes representing a comparison between 2 linked treatments. Size of the node is proportional to the number of patients randomized to that bowel preparation approach, and the thickness of the lines is proportional to the number of studies comparing the 2 approaches.
Figure 2. League Tables of the 8 Outcomes Showing Direct Comparisons and Indirect Comparisons Between Treatment Groups Based on Mechanical Bowel Preparation (MBP) and Oral Antibiotic (OAB) Status
Outcomes are shown as odds ratios (95% equal-tail credible intervals); direct comparisons are represented in bold, and indirect comparisons are represented in italics.
Figure 3. Rankograms of the 8 Outcomes Showing the Probability of Being Ranked the Best vs the Worst Based on Mechanical Bowel Preparation (MBP) and Oral Antibiotic (OAB) Status
Outcomes on the far left of the x-axis are ranked best; far right, worst.
Figure 4. Forest Plots of the 8 Outcomes Showing Direct Comparisons and Indirect Comparisons Based on Mechanical Bowel Preparation (MBP) and Oral Antibiotic (OAB) Status
Outcomes are shown as odds ratios (ORs) (95% equal-tail credible intervals [CrIs]).